苯丙酸諾龍

化合物

苯丙酸諾龍(英語:Nandrolone phenylpropionate或 Nandrolone hydrocinnamic,縮寫NPP,商品名為Durabolin)是一種雄激素同化類固醇(AAS)藥物,主要用於治療乳腺癌骨質疏鬆症女性[8][9][10][11][3],通過每周一次的肌肉注射進行[3]。這類藥物過去曾廣泛應用,但現已逐漸停用[3][11]

苯丙酸諾龍
臨床資料
商品名英語Drug nomenclatureDurabolin, others
其他名稱• NPP
• Nandrolone phenpropionate
• 19-Nortestosterone phenylpropionate
• Nandrolone hydrocinnamate
• 19-Nortestosterone 17β-phenylpropionate
• NSC-23162
懷孕分級
  • : D
給藥途徑Intramuscular injection
藥物類別英語Drug classAndrogen; Anabolic steroid; Androgen ester; Progestogen
法律規範狀態
法律規範
藥物動力學數據
生物利用度Oral: 0.3–2.9% (pigs)[1]
Intramuscular: high[2]
藥物代謝Blood (hydrolysis), liver (reduction)[7][5]
代謝產物Nandrolone[3]
5α-Dihydronandrolone[3]
19-Norandrosterone[4]
19-Noretiocholanolone[4]
Conjugates[5]
生物半衰期• Intramuscular: 2.7 days[6]
• Nandrolone: <4.3 hours[7]
作用時間• Intramuscular: 5–7 days[3][6]
排泄途徑Urine[7]
識別資訊
  • [(8R,9S,10R,13S,14S,17S)-13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl] 3-phenylpropanoate
CAS號434-22-0
PubChem CID
ChemSpider
UNII
CompTox Dashboard英語CompTox Chemicals Dashboard (EPA)
ECHA InfoCard100.000.502 編輯維基數據鏈接
化學資訊
化學式C27H34O3
摩爾質量406.57 g·mol−1
3D模型(JSmol英語JSmol
  • C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)CCC4=CC=CC=C4)CCC5=CC(=O)CC[C@H]35
  • InChI=1S/C27H34O3/c1-27-16-15-22-21-11-9-20(28)17-19(21)8-10-23(22)24(27)12-13-25(27)30-26(29)14-7-18-5-3-2-4-6-18/h2-6,17,21-25H,7-16H2,1H3/t21-,22+,23+,24-,25-,27-/m0/s1
  • Key:UBWXUGDQUBIEIZ-QNTYDACNSA-N
19-去甲睪酮(Nandrolone,諾龍),NPP的最終活性形式

參考文獻

編輯
  1. ^ McEvoy JD, McVeigh CE, McCaughey WJ. Residues of nortestosterone esters at injection sites. Part 1. Oral bioavailability. Analyst. 1998, 123 (12): 2475–8. PMID 10435281. doi:10.1039/a804919j. 
  2. ^ Kenneth L. Becker. Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. 2001: 1185– [2019-02-17]. ISBN 978-0-7817-1750-2. (原始內容存檔於2020-05-17). 
  3. ^ 3.0 3.1 3.2 3.3 3.4 3.5 William Llewellyn. Anabolics. Molecular Nutrition Llc. 2011: 460–467,193–194. ISBN 978-0-9828280-1-4. 
  4. ^ 4.0 4.1 Victor A. Rogozkin. Metabolism of Anabolic-Androgenic Steroids. CRC Press. 14 June 1991: 108–. ISBN 978-0-8493-6415-0. 
  5. ^ 5.0 5.1 John A. Thomas. Drugs, Athletes, and Physical Performance. Springer Science & Business Media. 6 December 2012: 27–29. ISBN 978-1-4684-5499-4. 
  6. ^ 6.0 6.1 Minto CF, Howe C, Wishart S, Conway AJ, Handelsman DJ. Pharmacokinetics and pharmacodynamics of nandrolone esters in oil vehicle: effects of ester, injection site and injection volume. J. Pharmacol. Exp. Ther. 1997, 281 (1): 93–102. PMID 9103484. 
  7. ^ 7.0 7.1 7.2 存档副本 (PDF). [2019-02-17]. (原始內容 (PDF)存檔於2010-12-18). 
  8. ^ J. Elks. The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. 14 November 2014: 660–. ISBN 978-1-4757-2085-3. 
  9. ^ Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000: 716–717. ISBN 978-3-88763-075-1. 
  10. ^ I.K. Morton; Judith M. Hall. Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. 6 December 2012. ISBN 978-94-011-4439-1. 
  11. ^ 11.0 11.1 存档副本. [2019-02-17]. (原始內容存檔於2019-08-28).